A phase I study of cetuximab in combination with paclitaxel in patients with advanced-stage breast cancer

Clinical Breast Cancer

Volumn 7, Issue 3, 2006, Pages 270-277

  Modi, Shanu ^a   D'Andrea, Gabriella ^a   Norton, Larry ^a   Yao, Tzy Jyun ^a   Caravelli, James ^a   Rosen, Peter P ^a   Hudis, Clifford ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical trials; Dose escalation; Metastatic breast cancer; Rash; Toxicity

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CETUXIMAB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; STEROID; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLICULITIS; GASTRITIS; HEADACHE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LIVER TOXICITY; MACULOPAPULAR RASH; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PAIN; PHASE 1 CLINICAL TRIAL; SENSORY DYSFUNCTION; SKIN EDEMA; SKIN TOXICITY; STOMATITIS; VOMITING;

EID: 33749011681     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.040     Document Type: Article

References (30)

1. Fitzpatrick SL, LaChance MP, Schultz GS. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res 1984; 44:3442-3447.
2. Fitzpatrick SL, Brightwell J, Wittliff JL, et al. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 1984; 44:3448-3453.
3. Klijn JGM, Berns PMJJ, Schmitz PIM, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13:3-17.
4. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000; 103:211-225.
5. Modi S, Seidman AD. An update on epidermal growth factor receptor inhibitors. Current Oncol Rep 2002; 4:47-55.
6. Albain K, Elledge R, Gradishar WJ, et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76(suppl 1):S33 (Abstract #20).
7. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76(suppl 1):S115 (Abstract #445).
8. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22:3080-3090.
9. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-1418.
10. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44:1002-1007.
11. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327-1333.
12. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997; 89:341-343.
13. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708.
14. Wen XZ, Li C, Wu Q-P, et al. Potentiation of antitumour activity of PG-TXL with anti-EGFR monoclonal antibody C225 in MDA-MB468 human breast cancer xenograft. Proc Am Assoc Cancer Res 2000; 41:323 (Abstract #2052).
15. Food and Drug Administration [Website]. FDA labeling information. Available at: http://www.fda.gov/cder/foi/label/2004/125084lbl.pdf. Accessed November 30, 2005.
16. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-914.
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
18. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
19. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck: results of a phase II study. Proc Am Soc Clin Oncol 2004; 23:487 (Abstract #5502)
20. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of patients with epidermal growth factor receptor-expressing advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:618 (Abstract #7012).
21. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol 2005; 23:1760-1775.
22. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody Imclone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
23. Seidman AD, Hudis CA, Albanel J, et al. Dose dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361.
24. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23:8786-8793.
25. Aghajanian C, Sabbatini P, Derosa F, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 2005; 24(16 suppl):466 (Abstract #5047).
26. Clark GM, Perez-Soler, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCL. Proc Am Soc Clin Oncol 2003; 22:196 (Abstract #786).
27. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22:204 (Abstract #817).
28. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
29. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
30. Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. Oncology 1999; 13:647-658.